Cargando…

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape

PURPOSE: Acute myeloid leukemia (AML) is a highly heterogeneous neoplastic disease with a poor prognosis that relapses even after its treatment with chimeric antigen receptor (CAR)-T cells targeting a single antigen. CD123 and CLL1 are expressed in most AML blasts and leukemia stem cells, and their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Danni, Jin, Xin, Sun, Rui, Zhang, Meng, Lu, Wenyi, Cao, Xinping, Guo, Ruiting, Zhang, Yi, Zhao, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302120/ https://www.ncbi.nlm.nih.gov/pubmed/37224766 http://dx.doi.org/10.1016/j.tranon.2023.101695

Ejemplares similares

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
por: Jin, Xin, et al.
Publicado: (2023)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
por: Cao, Xinping, et al.
Publicado: (2023)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions
por: Lam, Norris, et al.
Publicado: (2023)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
por: Guo, Ruiting, et al.
Publicado: (2022)

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
por: Tian, Meijie, et al.
Publicado: (2022)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy
por: Wang, Jiaxi, et al.
Publicado: (2023)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy
por: Wu, Haibin, et al.
Publicado: (2021)

Characterization of Bicistronic Transcription in Budding Yeast
por: Wu, Baojun, et al.
Publicado: (2021)

Bicistronic DNA Vaccines Simultaneously Encoding HIV, HSV and HPV Antigens Promote CD8(+) T Cell Responses and Protective Immunity
por: Santana, Vinicius C., et al.
Publicado: (2013)

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
por: Xie, L H, et al.
Publicado: (2017)

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

Selection-free endogenous tagging of cell lines by bicistronic co-expression of the surface antigen NGFR
por: Seibert, Marcel, et al.
Publicado: (2022)

Systematic analysis of bicistronic reporter assay data
por: Jacobs, Jonathan L., et al.
Publicado: (2004)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
por: Wang, Jinghua, et al.
Publicado: (2018)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020)

IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell
por: Sun, Yao, et al.
Publicado: (2019)

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
por: Collins, McKensie A., et al.
Publicado: (2022)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hq589echdf2qpea9l851j8se5f